PMID- 16019486
OWN - NLM
STAT- MEDLINE
DCOM- 20051005
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 46
IP  - 4
DP  - 2005 Apr
TI  - Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow 
      transplantation induce effective anti-tumor immune responses.
PG  - 571-80
AB  - In allogeneic hematopoietic stem cell (HSC) transplantation, graft vs. tumor 
      (GVT) activity contributes to the cancer cure. It is closely associated with 
      graft vs. host disease (GVHD), an immune response initiated by transplanted donor 
      T-cell responses against host minor histocompatibility antigens (mHAgs). GVHD is 
      prevented by T-cell depletion of the donor graft, but T-cell depletion also 
      abrogates curative GVT. We wished to test the hypothesis that cellular tumor 
      vaccines administered after T cell-depleted HSC transplant can induce significant 
      GVT effects, despite the absence of transplanted mature donor T cells. In this 
      investigation, a murine model of major histocompatibility complex (MHC)-matched, 
      mHAg-mismatched allogeneic HSC transplant was studied. T cell-depleted or normal 
      T cell-containing grafts were given to myeloablated recipients. Following 
      reconstitution the recipients were vaccinated with tumor vaccines. GVT responses 
      were measured in vitro by T-cell function assays and flow cytometry, and in vivo 
      by tumor burden or survival. Post-transplant tumor vaccines induced effective 
      anti-tumor responses in recipients of T cell-depleted transplants, producing 
      cytolytic and cytokine responses, reduced tumor burden and prolonged survival. 
      Recipients of T cell-depleted transplants that still have significant thymic 
      function may be suitable subjects for post-transplant vaccine therapy.
FAU - Mundhada, Shailendra
AU  - Mundhada S
AD  - Department of Pediatrics, University of Texas M.D. Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Shaw, Joanne
AU  - Shaw J
FAU - Mori, Shahram
AU  - Mori S
FAU - Savary, Cherylyn A
AU  - Savary CA
FAU - Mullen, Craig A
AU  - Mullen CA
LA  - eng
GR  - 1R01CA10628-01/CA/NCI NIH HHS/United States
GR  - 5T32CA073954-05/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation/adverse effects/*immunology
MH  - Cancer Vaccines/*administration & dosage/immunology
MH  - Cell Line
MH  - Disease Models, Animal
MH  - Female
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Graft vs Tumor Effect/immunology
MH  - Histocompatibility Antigens/immunology
MH  - Immunotherapy, Active
MH  - *Lymphocyte Depletion
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Mice, Inbred C57BL
MH  - Neoplasms, Experimental/immunology/*therapy
MH  - T-Lymphocytes/*immunology
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2005/07/16 09:00
MHDA- 2005/10/06 09:00
CRDT- 2005/07/16 09:00
PHST- 2005/07/16 09:00 [pubmed]
PHST- 2005/10/06 09:00 [medline]
PHST- 2005/07/16 09:00 [entrez]
AID - L33L67WX73173W55 [pii]
AID - 10.1080/10428190500032596 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2005 Apr;46(4):571-80. doi: 10.1080/10428190500032596.